Name of oncologist:

Contact number:

After-hours contact number:

My name:

My contact number:

Emergency contact:

Emergency contact number:

Important Information for Health Care Providers

This patient is being treated with Tecentriq® (atezolizumab), which can cause immune-mediated adverse reactions. Early diagnosis and appropriate management are essential to minimise any consequences of immune-mediated adverse reactions.

For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, withhold Tecentriq and administer corticosteroids. Specific guidelines for managing immune-mediated adverse reactions are provided in the Summary of Product Characteristics.

Please contact the patient's Oncologist (details on the left) for more information.

Assess patients for signs and symptoms of pneumonitis, hepatitis, colitis, endocrinopathies (including hypophysitis, adrenal insufficiency, type 1 diabetes mellitus, hypothyroidism, hyperthyroidism), myocarditis, pericardial disorder, pancreatitis, nephritis, myositis, hemophagocytic lymphohistiocytosis, severe cutaneous adverse reactions and infusion related reactions. Other immune-mediated adverse reactions reported in patients receiving atezolizumab include: neuropathies (Guillain-Barré syndrome, myasthenic syndrome / Myasthenia Gravis, facial paresis), myelitis and meningoencephalitis.

Please consult **Summary of Product Characteristics** for Tecentriq available at www.medicines.org.uk/emc if based in Great Britain or www.emcmedicines.com/en-gb/northernireland if based in Northern Ireland or contact Roche Medical Information
Tel: 0800328 1629
email: medinfo.uk@roche.com

By reporting side effects you can help provide more information on the safety of this medicine. You can report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
You should also report side effects to Roche Products Ltd. by emailing the Roche Drug Safety Centre at welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

Roche

Patient Card
Tecentriq® (atezolizumab)

M-GB-00014001 Date of preparation: September 2023
v9.0.2
MHRA Approval Date: 22/09/2023

IMPORTANT:

Tecentriq® (atezolizumab) can cause serious side effects in many parts of your body that need to be treated right away

Symptoms may occur at any time during treatment or even after your treatment has ended

Call your doctor **right away** if you develop any of these new signs or symptoms listed on this card or if your symptoms should get worse

Also tell your doctor if you experience any other symptoms not listed on this card

Do not try to treat your symptoms on your own

Carry this card with you at all times, especially when you travel, whenever you go to the Accident and Emergency department, or when you see another doctor.

IMPORTANT Reminders for Patients

Like all medicines, Tecentriq (atezolizumab) may cause side-effects, although not everybody gets them. It is important to tell your doctor immediately if you develop any of the signs or symptoms listed on this card after starting treatment with atezolizumab.

You should not start any other medicines during your treatment without talking to your doctor first.

If you develop any signs or symptoms listed on this card or if you notice any signs or symptoms not listed on this card, please contact your doctor immediately.

If you have any further questions about your treatment or on the use of this medicine, please contact your doctor.

SELECT IMPORTANT SAFETY INFORMATION

Serious side effects may include problems with your:

Lungs (pneumonitis): new or worsening cough, shortness of breath, chest pain

Liver (hepatitis): yellowing of skin or the whites of eyes, severe nausea or vomiting, bleeding or bruising, dark urine, stomach pain

Intestines (colitis): diarrhoea (watery, loose or soft stools), blood in stools, stomach pain

Hormone glands (for example hypothyroidism or diabetes): extreme tiredness, weight loss, weight gain, change in mood, hair loss, constipation, dizziness, feeling more hungry or thirsty than usual, need to urinate more often, increased sensitivity to cold or heat

Brain (meningoencephalitis): neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion, sleepiness

Musculoskeletal (myositis): inflammation or damage of the muscles, muscle pain and weakness.

Nerves (neuropathies or myelitis): abnormal sensations such as numbness, coldness or burning, bladder and bowel problems, weakness in the arm and leg muscles, or face muscles, double vision, difficulties with speech and chewing, pain, stiffness, and tingling in your hands and feet

Pancreas (pancreatitis): abdominal pain, nausea, vomiting

Heart (myocarditis, pericardial disorder): chest pain which could worsen with deep breathing, shortness of breath, irregular heartbeat, decreased exercise tolerance, swelling of the ankles, legs or abdomen, cough, fatigue, fainting

Kidneys (nephritis): changes in urine output and colour, pain in pelvis, and swelling of the body

Skin (severe skin reactions (SCARs)): rash, itching, skin blistering, peeling or sores, and/or ulcers in the mouth or in lining of the nose, throat or genital area

Build-up of certain white blood cells (histiocytes and lymphocytes) in various organs system (hemophagocytic lymphohistiocytosis) can result in symptoms such as enlarged liver and/or spleen, skin rash, lymph node enlargement, breathing problems, easy bruising, kidney abnormalities, and heart problems

Reactions associated with infusion (during or within 1 day of treatment administration): fever, chills, shortness of breath, flushing.

This list of symptoms is not exhaustive. Please refer to the Patient leaflet (PIL) for Tecentriq available at www.medicines.org.uk/emc if based in Great Britain or www.emcmedicines.com/en-gb/northernireland if based in Northern Ireland.

Getting medical treatment immediately may stop the problems from becoming serious. Your doctor may decide to give you other medicines to prevent complications and reduce your symptoms, and may withhold the next dose or stop your treatment.

This educational material is provided by Roche Products Ltd. and mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.

IMPORTANT:

It is important that you carry this card **with you at all times, including after stopping treatment**.

Please ensure you show this card to **all Healthcare Professionals** involved in your treatment and care.